05:39 PM EST, 11/17/2025 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) stated in a Monday regulatory filing it plans to lodge a patent infringement lawsuit against Sandoz for submitting an abbreviated new drug application to the US Food and Drug Administration to manufacture or sell a generic version of the company's Livmarli drug to treat cholestatic pruritus.

In a notice sent to Mirum, Sandoz claimed that five of the patents listed in the FDA Orange Book for Livmarli will not be infringed by Sandoz's generic product, according to the filing.

The company said it seeks a permanent injunction to prevent companies from launching a generic version of Livmarli that would infringe its patents.

Sandoz did not immediately respond to a request for comment from MT Newswires.

Mirum stock is down 2% during after-hours activity.